A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

This study investigated the efficacy and safety of dacomitinib in advanced, refractory non–small cell lung cancer (NSCLC), selecting for patients with KRAS wild‐type tumors to exclude those least likely, and simultaneously enrich for those most likely, to benefit from therapy. Although the observed...

Descripción completa

Detalles Bibliográficos
Autores principales: Reckamp, Karen L., Giaccone, Giuseppe, Camidge, D. Ross, Gadgeel, Shirish M., Khuri, Fadlo R., Engelman, Jeff A., Koczywas, Marianna, Rajan, Arun, Campbell, Alicyn K., Gernhardt, Diana, Ruiz‐Garcia, Ana, Letrent, Stephen, Liang, Jane, Taylor, Ian, O'Connell, Joseph P., Jänne, Pasi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164026/
https://www.ncbi.nlm.nih.gov/pubmed/24501009
http://dx.doi.org/10.1002/cncr.28561
_version_ 1782334902036856832
author Reckamp, Karen L.
Giaccone, Giuseppe
Camidge, D. Ross
Gadgeel, Shirish M.
Khuri, Fadlo R.
Engelman, Jeff A.
Koczywas, Marianna
Rajan, Arun
Campbell, Alicyn K.
Gernhardt, Diana
Ruiz‐Garcia, Ana
Letrent, Stephen
Liang, Jane
Taylor, Ian
O'Connell, Joseph P.
Jänne, Pasi A.
author_facet Reckamp, Karen L.
Giaccone, Giuseppe
Camidge, D. Ross
Gadgeel, Shirish M.
Khuri, Fadlo R.
Engelman, Jeff A.
Koczywas, Marianna
Rajan, Arun
Campbell, Alicyn K.
Gernhardt, Diana
Ruiz‐Garcia, Ana
Letrent, Stephen
Liang, Jane
Taylor, Ian
O'Connell, Joseph P.
Jänne, Pasi A.
author_sort Reckamp, Karen L.
collection PubMed
description This study investigated the efficacy and safety of dacomitinib in advanced, refractory non–small cell lung cancer (NSCLC), selecting for patients with KRAS wild‐type tumors to exclude those least likely, and simultaneously enrich for those most likely, to benefit from therapy. Although the observed response rate was low, a number of patients experienced prolonged disease control accompanied by rapid and durable lung cancer symptom relief, suggesting that dacomitinib has relevant activity against KRAS wild‐type NSCLC.
format Online
Article
Text
id pubmed-4164026
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Wiley
record_format MEDLINE/PubMed
spelling pubmed-41640262014-09-22 A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib Reckamp, Karen L. Giaccone, Giuseppe Camidge, D. Ross Gadgeel, Shirish M. Khuri, Fadlo R. Engelman, Jeff A. Koczywas, Marianna Rajan, Arun Campbell, Alicyn K. Gernhardt, Diana Ruiz‐Garcia, Ana Letrent, Stephen Liang, Jane Taylor, Ian O'Connell, Joseph P. Jänne, Pasi A. Cancer Original Articles This study investigated the efficacy and safety of dacomitinib in advanced, refractory non–small cell lung cancer (NSCLC), selecting for patients with KRAS wild‐type tumors to exclude those least likely, and simultaneously enrich for those most likely, to benefit from therapy. Although the observed response rate was low, a number of patients experienced prolonged disease control accompanied by rapid and durable lung cancer symptom relief, suggesting that dacomitinib has relevant activity against KRAS wild‐type NSCLC. Wiley 2014-04-08 2014-02-05 /pmc/articles/PMC4164026/ /pubmed/24501009 http://dx.doi.org/10.1002/cncr.28561 Text en © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/3.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Reckamp, Karen L.
Giaccone, Giuseppe
Camidge, D. Ross
Gadgeel, Shirish M.
Khuri, Fadlo R.
Engelman, Jeff A.
Koczywas, Marianna
Rajan, Arun
Campbell, Alicyn K.
Gernhardt, Diana
Ruiz‐Garcia, Ana
Letrent, Stephen
Liang, Jane
Taylor, Ian
O'Connell, Joseph P.
Jänne, Pasi A.
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
title A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
title_full A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
title_fullStr A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
title_full_unstemmed A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
title_short A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
title_sort phase 2 trial of dacomitinib (pf‐00299804), an oral, irreversible pan‐her (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164026/
https://www.ncbi.nlm.nih.gov/pubmed/24501009
http://dx.doi.org/10.1002/cncr.28561
work_keys_str_mv AT reckampkarenl aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT giacconegiuseppe aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT camidgedross aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT gadgeelshirishm aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT khurifadlor aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT engelmanjeffa aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT koczywasmarianna aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT rajanarun aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT campbellalicynk aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT gernhardtdiana aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT ruizgarciaana aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT letrentstephen aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT liangjane aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT taylorian aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT oconnelljosephp aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT jannepasia aphase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT reckampkarenl phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT giacconegiuseppe phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT camidgedross phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT gadgeelshirishm phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT khurifadlor phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT engelmanjeffa phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT koczywasmarianna phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT rajanarun phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT campbellalicynk phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT gernhardtdiana phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT ruizgarciaana phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT letrentstephen phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT liangjane phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT taylorian phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT oconnelljosephp phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib
AT jannepasia phase2trialofdacomitinibpf00299804anoralirreversiblepanherhumanepidermalgrowthfactorreceptorinhibitorinpatientswithadvancednonsmallcelllungcancerafterfailureofpriorchemotherapyanderlotinib

Ejemplares similares